Updated event details for The 22nd Planova™ Workshop
We look forward to hosting you at the upcoming 22nd Planova™ Workshop in Lisbon where professionals from around the world will gather to share their expertise on topics such as virus filtration fundamentals, process development, robust manufacturing and new trends.
Confirmed chairs, speakers and tentative presentation titles are shown below.
Thomas R. Kreil, Ph.D.
Vice President, Global Pathogen Safety, Takeda Pharmaceutical Company
Uwe Gottschalk, Ph.D.
Chief Scientific Officer, Pharma Biotech & Nutrition R&D, Lonza AG
Salvador Grancha, Ph.D.
Vice President, Research & Development, Grifols
Nathan J. Roth, Ph.D.
Executive Director, Global Pathogen Safety, R&D, CSL Behring
Speakers and Presentations
Strategies for Controlling Virus Risk in Upstream Processes
Andy Bailey, Ph.D., CEO & Operations Director, ViruSure
Regulatory Developments in Viral Safety
Johannes Blümel, Ph.D., Head of Virus Safety Section, Department of Virology, Paul-Ehrlich-Institut
Next Generation Processes: Challenges and Considerations for Robust Validation of Viral Filtration Applications
James Eagles, MS&T Purification Scientist, Manufacturing Science & Technology, Bristol-Myers Squibb
Process Development and Impact of Critical Process Parameters on Virus Filtration
Walter Elffrink B.Sc., Senior Research Technician, Synthon Biopharmaceuticals
Overview of Challenges in Virus Filtration: Principles and Applications
Tomoko Hongo-Hirasaki, Ph.D., Lead Expert, Global Marketing, Scientific Affairs, Bioprocess Division, Asahi Kasei Medical
Investigation of the Virus Particle and Number Based-Virus Filter Evaluation
Taiki Kayukawa, Scientist, Technology Development Department, Bioprocess Division, Asahi Kasei Medical
Quantitative Visualization of Virus Behavior in Planova™ Membrane Filters Using Optical Microscope
Takayuki Nishizaka, Ph.D.,Professor, Department of Physics, Gakushuin University
Choice of Parvovirus Model (MVM, CPV, PPV) Influences the Interpretation of the Effectiveness of Virus Filtration Step
Thomas Nowak, Ph.D., Senior Manager, Global Pathogen Safety, CSL Behring
Implementation of Virus Removing Filtration - Challenges to Overcome
Ingrid M.M. Prins-de Nijs, Project Leader Product Development, Sanquin Plasma Products B.V.
Robust Virus Removal in Boehringer Ingelheim's Downstream Platform Processes
Simon Reitz, Ph.D., Associate Director Protein Science, BioProcess + Analytical Dev., Boehringer Ingelheim
Practical Approach to Evaluating the Removal of Membrane-Associated Non-Enveloped Virus by Nanofiltration Membrane
Kaoru Sakai, Ph.D., Associate General Manager, Central Research Laboratory, Research & Development Division, Japan Blood Products Organization
Low Flux Impacts on Virus Filtration: The Devil is in the Details
Daniel Strauss, Ph.D., Principal Scientist, Science and Technology, Asahi Kasei Bioprocess America
A Non-enveloped Virus with a Lipid Envelope: Antibody-Enhanced Hepatitis E Virus Nanofiltration During the Manufacture of Human Immunoglobulin
Andreas Wieser, DI (Fh), Senior Lab Associate, Global Pathogen Safety, Takeda Pharmaceutical Company
Adoption of the Planova™ BioEX to a Platform Process
John Zehmer, Ph.D., Scientist III, Purification Sciences - Late Stage Development, MacroGenics
We would be honored to host you in the beautiful city of Lisbon. Additional information will be released in upcoming announcements and on The 22nd Planova™ Workshop Page.